SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pålhagen Sven E)
 

Sökning: WFRF:(Pålhagen Sven E) > (2020-2021) > Swedish guidelines ...

Swedish guidelines for device-aided therapies in Parkinson's disease —Economic evaluation and implementation

Norlin, Jenny M. (författare)
IHE – The Swedish Institute for Health Economics
Willis, Michael (författare)
IHE – The Swedish Institute for Health Economics
Persson, Ulf (författare)
IHE – The Swedish Institute for Health Economics
visa fler...
Andersson, Emelie (författare)
IHE – The Swedish Institute for Health Economics
E. Pålhagen, Sven (författare)
Karolinska Institute,Skåne University Hospital
Odin, Per (författare)
Lund University,Lunds universitet,Neurologi, Lund,Sektion IV,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Restorative Parkinson Unit,Forskargrupper vid Lunds universitet,Neurology, Lund,Section IV,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups
visa färre...
 (creator_code:org_t)
2021-04-26
2021
Engelska.
Ingår i: Acta Neurologica Scandinavica. - : Hindawi Limited. - 0001-6314 .- 1600-0404. ; 144:2, s. 170-178
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Objectives: The National Board of Health and Welfare in Sweden published the national guidelines for Parkinson's Disease 2016. The aim of this study was to summarize this evidence review and development of the guidelines, focusing on the economic evaluation of device-aided therapies (deep brain stimulation, pump-based infusion of levodopa-carbidopa intestinal gel or apomorphine) for Parkinson's disease, and the rate of implementation after 3 years in Sweden. Material and methods: The evidence review underlying the guidelines—including systematic literature searches of clinical and economic evidence, model-based economic evaluation, and formal analysis and guideline development—was examined, condensed, and translated. The impact of the guidelines was assessed with treatment use statistics from 2009 to 2019. Results: All device-aided therapies were assigned high priority. Based on a relatively low proportion of device-aided therapies (30%) in Parkinson's disease, a 5-year increase of 500 patients was recommended. This was estimated to reduce total costs by SEK 14 million (€1.7 million). Follow-up data found an increase of 217 patients between 2017 and 2019, following the same trend as before the guidelines. Conclusion: Three years after the guidelines were published, the use of device-aided therapies has increased in Sweden, albeit not in pace with recommendations. One reason for slow implementation may be poor incentivization related to budget silos in which the costs for device-aided therapies are borne by the regions but the cost offsets (eg, reduced need for home care) are reaped by local stakeholders.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

National Guidelines
Parkinson's disease
Sweden
​Cost-effectiveness
​Device-​Aided ​Therapies
​Economic model
​Literature review

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy